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The Liverpool Statement 2005 was developed at the Fourth Inter-
national Lung Cancer Molecular Biomarkers Workshop in Liver-
pool (October 27-29, 2005) and focused on the priorities for the
European Union/United States (EU-US) Spiral Computed Tomog-
raphy (CT) Collaborative Group. The application of spiral CT
technology for early lung cancer screening has gained enormous
momentum in the past 5 years. The EU-US Spiral CT Collaboration
was initiated in 2001 in Liverpool, and subsequent meetings
throughout Europe have resulted in the development of collaborative
protocols and minimal data sets that provide a mechanism for the
different trial groups to work together, with the ultimate aim to pool
results. Considerable progress has been made with major national
screening trials in the U.S. and Europe, which include IELCAP,
NLST, and NELSON. The major objective of this international
collaboration is the planned cross-analysis of the individual studies
after they are reported. The EU-US researchers have agreed to a
number of long-term objectives and to explore strategic areas for
harmonization of complementary investigations.
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Lung cancer is a health problem of global proportions. Lungcancer is the most common cancer in the world, with a
disproportionate number of cases occurring in the developed
world. Despite intensive research over many years, the prog-
nosis is still very poor, with less than 15% of the patients
surviving 5 years after primary diagnosis in the U.S. and even
fewer (5-10%) surviving in Europe and other countries. The
poor survival is mainly attributable to the lack of effective
treatment for systemic disease and the fact that more than
two-thirds of patients present with regional or distant metas-
tases. The best way to control the future incidence of lung
cancer is to reduce cigarette smoking in the population,
primarily through prevention and secondarily through smok-
ing cessation. However, even after stopping smoking, long-
term smokers remain at high risk of lung cancer.
The application of spiral CT technology for early lung
cancer screening has gained enormous momentum in the past
5 years,1 and international approval for this approach is being
sought through the gold standard scientific methodology, i.e.,
randomized controlled trials, before implementation by any
national health care system will be considered. In 2001, it was
our judgment that an international collaborative approach was
required to achieve this objective.2
The EU-US Spiral CT Collaboration was initiated in
2001 in Liverpool, and subsequent meetings throughout Eu-
rope over the ensuing 3 years resulted in the development of
collaborative protocols and minimal data sets that provide a
mechanism for the different trial groups to work together,
with the ultimate aim to pool results. These protocols are
currently in press.
Considerable progress has been made, with major na-
tional screening trials underway in the U.S.A. and Europe.
Indeed, the NLST trial (United States National Lung Screen-
ing Trial) has completed accrual of the target of 50,000
subjects, and annual screening is on schedule.3 The ongoing
NELSON trial4 (Nederlands Leuvens Longkanker Screenings
Onderzoek) in the Netherlands, Belgium, and Denmark is
making significant progress toward the accrual of 20,000
subjects, together with the contribution of the ongoing
Italung-CT project in Italy (3,000 subjects) and the possible
trials in Germany and the United Kingdom. The accruing of
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all these cohorts may provide a study population of more than
30,000 individuals in Europe.
The large I-ELCAP (The International-Early Lung
Cancer Action Project) trial has accrued more than 30,000
subjects at baseline and has a large portion of subjects
engaged in annual follow-ups. The ELCAP group also has
contributed to the literature on the management and surveil-
lance of small lesions detected with spiral CT.5
Since the initiation of these trials, there have been
major refinements in many aspects of the quality control and
clinical management processes; however, considerable fur-
ther work is required. To ensure ongoing progress, further
international cooperation among major screening research
groups is essential. The major objective of this international
collaboration is the eventual cross-analysis of the individual
studies. The major unresolved issue is the problem of recon-
ciling whether pooled analysis of lung cancer mortality would
yield an answer to the question of efficacy some years before
any individual study.
The achievements and long-term objectives of the
EU-US Spiral CT Collaboration are:
Y This collaboration engaged all of the potential partici-
pants in the EU and U.S.A. before the initialization of
the spiral CT early-detection randomized controlled tri-
als (RCTs). This enabled frank discussions on the
strengths and weaknesses of trial designs, radiological
and pathological protocols, and minimal data sets.
Y This is the first time cancer investigators from different
continents have agreed to set up collaborative principles
before the initiation and agreed to fund their own RCTs.
Y The collaboration has so far established common prac-
tice on many attributes of the study protocols, which will
facilitate future collaborative analyses and interpretation
of the results as a whole.
Y The long-term objective to pool the minimal data set has
been agreed in principle, to analyze the primary out-
comes.
Y In addition to the RCTs of spiral CT screening, demon-
stration projects within the I-ELCAP collaboration bring
a great deal of information on large numbers of screened
subjects, demonstrate the importance of the definition of
the regimen that defines a positive result and the recom-
mended work-up, show results of long-term follow-up
of treated and untreated cases of lung cancer, and inform
future screening policy.
Y The development of shared core protocols has greatly
assisted the primary investigators in obtaining funding
for their own trials, especially within Europe.
Y The acknowledged issues regarding radiology and pa-
thology interpretation have been counterbalanced by the
development of international review groups that have set
new standards of reporting in this fast-moving field.
Y The collaborative group has also faced the challenges of
how patients with small lesions should be treated, and
the group is currently setting the groundwork for treat-
ment trials post-surgery.
Y The collaborative group is actively monitoring the
changing technologies that affect potential health care
screening methods.
Y Ongoing work on methodological improvements for
incorporating data for differing trial designs.
Y Examining methodologies for the stratification of high-
risk populations for future implementation of national
spiral CT screening programs.
The workshop in Liverpool paid particular attention to
the developing molecular genetic technologies and ap-
proaches that may assist in the identification of high-risk
populations for future screening and intervention strategies.
The enormous potential of molecular-epidemiology risk mod-
eling will provide a backbone to the future methodologies
that will be used to identify high-risk populations.
In light of the continued rapid improvements in the
capabilities of spiral CT and the promise of computer-aided
image processing tools, cooperation to catalyze the validation
of these tools in population-based applications is a priority.
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